{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:47:40Z","timestamp":1782899260483,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017003","name":"Peking University Health Science Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L248052"],"award-info":[{"award-number":["L248052"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2501001"],"award-info":[{"award-number":["2021YFC2501001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.drup.2025.101299","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:48:53Z","timestamp":1757515733000},"page":"101299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3434-0218","authenticated-orcid":false,"given":"Caiyun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9833-2069","authenticated-orcid":false,"given":"Like","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-1382","authenticated-orcid":false,"given":"Chuanke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengchao","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.drup.2025.101299_bib1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-10-2687","article-title":"Placental growth factor upregulation is a host response to antiangiogenic therapy","volume":"17","author":"Bagley","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.drup.2025.101299_bib2","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-16-3153","article-title":"Homeobox B9 mediates resistance to Anti-VEGF therapy in colorectal cancer patients","volume":"23","author":"Carbone","year":"2017","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"1","key":"10.1016\/j.drup.2025.101299_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CAD.0000000000000301","article-title":"Combined inhibition of IL1, CXCR1\/2, and TGF\u03b2 signaling pathways modulates in-vivo resistance to anti-VEGF treatment","volume":"27","author":"Carbone","year":"2016","journal-title":"AntiCancer Drugs"},{"issue":"10","key":"10.1016\/j.drup.2025.101299_bib4","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-13-0011","article-title":"\u03921 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma","volume":"73","author":"Carbonell","year":"2013","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.drup.2025.101299_bib5","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1038\/onc.2017.1","article-title":"Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy","volume":"36","author":"Castro","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.drup.2025.101299_bib6","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/1535-7163.MCT-13-0753","article-title":"Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer","volume":"13","author":"Chiron","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101299_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.965277","article-title":"Tumor vessel co-option: the past & the future","volume":"12","author":"Cuypers","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.drup.2025.101299_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.drup.2025.101299_bib9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/molehr\/gau054","article-title":"A peptide inhibitor of synuclein-\u03b3 reduces neovascularization of human endometriotic lesions","volume":"20","author":"Edwards","year":"2014","journal-title":"Mol. Hum. Reprod."},{"issue":"5","key":"10.1016\/j.drup.2025.101299_bib10","first-page":"700","article-title":"High-grade glioma before and after treatment with radiation and avastin: initial observations","volume":"10","author":"Fischer","year":"2008","journal-title":"NeuroOncol."},{"key":"10.1016\/j.drup.2025.101299_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/526178","article-title":"Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept","volume":"2014","author":"Giordano","year":"2014","journal-title":"Gastroenterol. Res. Pract."},{"issue":"6","key":"10.1016\/j.drup.2025.101299_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/ijc.22763","article-title":"Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer","volume":"121","author":"Guo","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2025.101299_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to Anti-angiogenic therapies in cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2025.101299_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-005-6938-0","article-title":"Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells","volume":"94","author":"Inaba","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.drup.2025.101299_bib15","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/ijms19041232","article-title":"Resistance to Anti-Angiogenic therapy in Cancer-Alterations to Anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.drup.2025.101299_bib16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1349-7006.2004.tb03183.x","article-title":"Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis","volume":"95","author":"Iwaki","year":"2004","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.drup.2025.101299_bib17","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/1078-0432.CCR-12-1281","article-title":"Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance","volume":"19","author":"Jahangiri","year":"2013","journal-title":"Clinical Cancer Research Official Journal American Association Cancer Research"},{"issue":"40","key":"10.1016\/j.drup.2025.101299_bib18","doi-asserted-by":"crossref","first-page":"30480","DOI":"10.1074\/jbc.M110.131698","article-title":"The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling","volume":"285","author":"Li","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.drup.2025.101299_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/15548627.2023.2249762","article-title":"Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer","volume":"20","author":"Li","year":"2024","journal-title":"Autophagy"},{"issue":"7","key":"10.1016\/j.drup.2025.101299_bib20","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.18632\/aging.204626","article-title":"Identification and validation of anoikis-associated gene SNCG as a prognostic biomarker in gastric cancer","volume":"15","author":"Li","year":"2023","journal-title":"Aging"},{"issue":"18","key":"10.1016\/j.drup.2025.101299_bib21","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/onc.2014.126","article-title":"Synuclein \u03b3 protects akt and mTOR and renders tumor resistance to Hsp90 disruption","volume":"34","author":"Liang","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2025.101299_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1471-2407-10-359","article-title":"Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen","volume":"10","author":"Liu","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.drup.2025.101299_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2008.04.037","article-title":"Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients","volume":"269","author":"Liu","year":"2008","journal-title":"Cancer Lett."},{"issue":"119","key":"10.1016\/j.drup.2025.101299_bib24","first-page":"2222","article-title":"Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas","volume":"59","author":"Liu","year":"2012","journal-title":"HepatoGastroenterol."},{"issue":"1","key":"10.1016\/j.drup.2025.101299_bib25","first-page":"117","article-title":"Extracellular gamma-synuclein promotes tumor cell motility by activating \u03b21 integrin-focal adhesion kinase signaling pathway and increasing matrix metalloproteinase-24, -2 protein secretion","volume":"37","author":"Liu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"issue":"28","key":"10.1016\/j.drup.2025.101299_bib26","doi-asserted-by":"crossref","first-page":"43432","DOI":"10.18632\/oncotarget.9468","article-title":"Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.drup.2025.101299_bib27","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.1158\/0008-5472.CAN-05-1089","article-title":"Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.drup.2025.101299_bib28","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.7150\/ijbs.69155","article-title":"Gamma synuclein promotes cancer metastasis through the MKK3\/6-p38MAPK cascade","volume":"18","author":"Liu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.drup.2025.101299_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00894-010-0718-4","article-title":"Insight into residues involved in the structure and function of the breast cancer associated protein human gamma synuclein","volume":"17","author":"Manivel","year":"2011","journal-title":"J. Mol. Model."},{"issue":"13","key":"10.1016\/j.drup.2025.101299_bib30","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.18632\/oncotarget.1671","article-title":"Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor","volume":"5","author":"M\u00e9sange","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.drup.2025.101299_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1535-7163.MCT-13-0671","article-title":"Synuclein \u03b3 compromises spindle assembly checkpoint and renders resistance to antimicrotubule drugs","volume":"13","author":"Miao","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2025.101299_bib32","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1038\/ncomms9792","article-title":"Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.drup.2025.101299_bib33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"issue":"28","key":"10.1016\/j.drup.2025.101299_bib34","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.2217\/fon-2022-0253","article-title":"A new biomarker for the early diagnosis of gastric cancer: gastric juice- and serum-derived SNCG","volume":"18","author":"Pan","year":"2022","journal-title":"Future Oncol. (Lond. Engl. )"},{"issue":"38","key":"10.1016\/j.drup.2025.101299_bib35","doi-asserted-by":"crossref","first-page":"35050","DOI":"10.1074\/jbc.M201650200","article-title":"Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways","volume":"277","author":"Pan","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.drup.2025.101299_bib36","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1039\/C3MB25427E","article-title":"Molecular dynamic simulations of the tubulin-human gamma synuclein complex: structural insight into the regulatory mechanism involved in inducing resistance against taxol","volume":"9","author":"Panneerselvam","year":"2013","journal-title":"Mol. Biosyst."},{"issue":"3","key":"10.1016\/j.drup.2025.101299_bib37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.celrep.2014.06.059","article-title":"Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade","volume":"8","author":"Rigamonti","year":"2014","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.drup.2025.101299_bib38","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.molonc.2014.05.011","article-title":"Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption","volume":"8","author":"Shao","year":"2014","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.drup.2025.101299_bib39","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ccell.2020.05.005","article-title":"Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer","volume":"37","author":"Shen","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.drup.2025.101299_bib40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.2353\/ajpath.2010.100061","article-title":"Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha","volume":"177","author":"Shi","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"16","key":"10.1016\/j.drup.2025.101299_bib41","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1073\/pnas.0902280106","article-title":"G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models","volume":"106","author":"Shojaei","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.drup.2025.101299_bib42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/0008-5472.CAN-06-1820","article-title":"Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.drup.2025.101299_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.253","article-title":"Radiation-induced gamma-synuclein in regards to DC function","volume":"6","author":"Song","year":"2015","journal-title":"Cell Death Dis."},{"issue":"18","key":"10.1016\/j.drup.2025.101299_bib44","first-page":"3964","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer","volume":"55","author":"Takahashi","year":"1995","journal-title":"Cancer Res."},{"issue":"44","key":"10.1016\/j.drup.2025.101299_bib45","doi-asserted-by":"crossref","first-page":"27435","DOI":"10.18632\/oncotarget.25415","article-title":"Synuclein gamma expression enhances radiation resistance of breast cancer cells","volume":"9","author":"Tian","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.drup.2025.101299_bib46","first-page":"1350","article-title":"VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1\/cMet in colon cancer cells","volume":"52","author":"Tomida","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.drup.2025.101299_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101887","article-title":"Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer","volume":"41","author":"Yan","year":"2024","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.drup.2025.101299_bib48","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.yexcr.2010.10.013","article-title":"Role of gamma-synuclein in microtubule regulation","volume":"317","author":"Zhang","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"21","key":"10.1016\/j.drup.2025.101299_bib49","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-23-0025","article-title":"Matrix stiffness triggers lipid metabolic Cross-talk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases","volume":"83","author":"Zheng","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.drup.2025.101299_bib50","first-page":"289","article-title":"Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment","volume":"29","author":"Zhou","year":"2006","journal-title":"Int. J. Oncol."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:20:11Z","timestamp":1772886011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764625001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"alternative-id":["S1368764625001025"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101299","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gamma-synuclein drives bevacizumab resistance in colorectal cancer via VEGFR2 activation and angiogenesis","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101299"}}